Tissue factor expression in ovarian cancer: Implications for immunotherapy with hI-con1, a factor VII-IgGF c chimeric protein targeting tissue factor

Clinical and Experimental Metastasis

Volumn 28, Issue 7, 2011, Pages 689-700

  Cocco, Emiliano ^a   Varughese, Joyce ^a   Buza, Natalia ^a   Bellone, Stefania ^a   Lin, Ken Yu ^a   Bellone, Marta ^a   Todeschini, Paola ^a   Silasi, Dan Arin ^a   Azodi, Masoud ^a   Schwartz, Peter E ^a   Rutherford, Thomas J ^a   Carrara, Luisa ^a   Tassi, Renata ^b   Pecorelli, Sergio ^b   Lockwood, Charles J ^a   Santin, Alessandro D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Cancer; Factor VII; Immunotherapy; Ovarian carcinoma; Tissue factor

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CD59 ANTIGEN; CISPLATIN; DECAY ACCELERATING FACTOR; DOXORUBICIN; GEMCITABINE; HI CON1 PROTEIN; IFOSFAMIDE; IMMUNOGLOBULIN G; INTERLEUKIN 2; MEMBRANE COFACTOR PROTEIN; PACLITAXEL; SMALL INTERFERING RNA; TOPOTECAN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL MEMBRANE; CHEMOSENSITIVITY; CHROMIUM 51 RELEASE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; DISEASE SEVERITY; EVALUATION; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; OVARY CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL LINE, TUMOR; FACTOR VII; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOTHERAPY; OVARIAN NEOPLASMS; THROMBOPLASTIN;

EID: 82355182088     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-011-9401-0     Document Type: Article

References (39)

1. A Jemal R Siegel J Xu E Ward 2010 Cancer statistics, 2010 CA Cancer J Clin 60 277 300 20610543 10.3322/caac.20073
2. KR Cho I Shih 2009 Ovarian cancer Annu Rev Pathol 4 287 313 18842102 10.1146/annurev.pathol.4.110807.092246 1:CAS:528:DC%2BD1MXis1aiu7k%3D
3. ES Bamberger CW Perrett 2002 Angiogenesis in epithelian ovarian cancer Mol Pathol 55 348 359 12456770 10.1136/mp.55.6.348 1:STN:280: DC%2BD38nps1agug%3D%3D (Pubitemid 35454510)
4. M Papetti IM Herman 2002 Mechanisms of normal and tumor-derived angiogenesis Am J Physiol Cell Physiol 282 947 970
5. J Contrino G Hair DL Kreutzer FR Rickles 1996 In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease Nat Med 2 209 215 8574967 10.1038/nm0296-209 1:CAS:528:DyaK28Xps1yluw%3D%3D (Pubitemid 26054985)
6. K Abe M Shoji J Chen A Bierhaus I Danave C Micko K Casper DL Dillehay PP Nawroth FR Rickles 1999 Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor Proc Natl Acad Sci USA 96 8663 8668 10411932 10.1073/pnas.96.15.8663 1:CAS:528: DyaK1MXkslOktL0%3D (Pubitemid 29354848)
7. HC Hollingsworth SM Steinberg SG Silverberg MJ Merino 1996 Advanced stage transitional cell carcinoma of the ovary Hum Pathol 27 1267 1272 8958296 10.1016/S0046-8177(96)90335-4 1:STN:280:DyaK2s7hslahtQ%3D%3D (Pubitemid 26415317)
8. W Ruf 2007 Tissue factor and PAR signaling in tumor progression Thromb Res 120 S7 S12 18023716 10.1016/S0049-3848(07)70125-1 (Pubitemid 350101768)
9. Z Hu Y Sun A Garen 1999 Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model Proc Natl Acad Sci USA 96 8161 8166 10393965 10.1073/pnas.96.14.8161 1:CAS:528:DyaK1MXltVOrsLw%3D (Pubitemid 29328425)
10. Z Hu A Garen 2000 Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy Proc Natl Acad Sci USA 97 9221 9225 10922073 10.1073/pnas.97.16.9221 1:CAS:528:DC%2BD3cXls12ksb4%3D (Pubitemid 30626701)
11. Z Hu A Garen 2001 Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer Proc Natl Acad Sci USA 98 12180 12185 11593034 10.1073/pnas.201420298 1:CAS:528:DC%2BD3MXns1Cjtr8%3D (Pubitemid 32959847)
12. E Waxman JB Ross TM Laue A Guha SV Thiruvikraman TC Lin WH Konigsberg Y Nemerson 1992 Tissue factor and its extracellular soluble domain: the relationship between intermolecular association with factor VIIa and enzymatic activity of the complex Biochemistry 31 3998 4003 1567850 10.1021/bi00131a015 1:CAS:528:DyaK38XhvFWltr0%3D
13. L Presta P Sims YG Meng P Moran S Bullens S Bunting J Schoenfeld D Lowe J Lai P Rancatore M Iverson A Lim V Chisholm RF Kelley M Riederer D Kirchhofer 2001 Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic Thromb Haemost 85 379 389 11307801 1:CAS:528:DC%2BD3MXis1yhsL8%3D (Pubitemid 32236672)
14. CD Dickinson CR Kelly W Ruf 1996 Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa Proc Natl Acad Sci USA 93 14379 14384 8962059 10.1073/pnas.93.25. 14379 1:CAS:528:DyaK28XnsVKksLk%3D (Pubitemid 26418974)
15. KA Gelderman S Tomlinson GD Ross A Gorter 2004 Complement function in mAb-mediated cancer immunotherapy Trends Immunol 25 3 158 164 15036044 10.1016/j.it.2004.01.008 1:CAS:528:DC%2BD2cXhsFWjurY%3D (Pubitemid 38249490)
16. CE Richter E Cocco S Bellone DA Silasi D Ruttinger M Azodi PE Schwartz TJ Rutherford S Pecorelli AD Santin 2010 High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody Am J Obstet Gynecol 203 582.e1 582.e7 10.1016/j.ajog.2010. 07.041 1:CAS:528:DC%2BC3cXhsVymsLfP
17. S Preithner S Elm S Lippold M Locher A Wolf AJ da Silva PA Baeuerle NS Prang 2006 High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G Mol Immunol 43 1183 1193 16102830 10.1016/j.molimm.2005.07.010 1:CAS:528:DC%2BD28XjsFKmsw%3D%3D (Pubitemid 43063171)
18. V Kaushal P Mukunyadzi ER Siegel RA Dennis DE Johnson M Kohli 2008 Expression of tissue factor in prostate cancer correlates with malignant phenotype Appl Immunohistochem Mol Morphol 16 1 6 18091328 1:CAS:528: DC%2BD1cXhsVSlsLs%3D
19. AD Santin PL Hermonat A Ravaggi M Chiriva-Internati D Zhan S Pecorelli GP Parham MJ Cannon 1999 Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer J Virol 73 5402 5410 10364287 1:CAS:528:DyaK1MXjvFyksr8%3D (Pubitemid 29274822)
20. ME O'Brien JB Schofield S Tan I Fryatt C Fisher E Wiltshaw 1993 Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages Gynecol Oncol 49 250 254 8504995 10.1006/gyno.1993.1117 (Pubitemid 23170001)
21. T Sugiyama T Kamura J Kigawa N Terakawa Y Kikuchi T Kita M Suzuki I Sato K Taguchi 2000 Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy Cancer 88 2584 2589 10861437 10.1002/1097-0142(20000601)88: 11<2584::AID-CNCR22>3.0.CO;2-5 1:STN:280:DC%2BD3cvisFyrtQ%3D%3D (Pubitemid 30331967)
22. H Itamochi J Kigawa T Sugiyama Y Kikuchi M Suzuki N Terakawa 2002 Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary Obstet Gynecol 100 281 287 12151151 10.1016/S0029- 7844(02)02040-9 (Pubitemid 34874791)
23. P Alessi C Ebbinghaus D Neri 2004 Molecular targeting of angiogenesis Biochim Biophys Acta 1654 39 49 14984766 1:CAS:528:DC%2BD2cXhsVKhsbw%3D (Pubitemid 38230930)
24. T Satoh A Oki K Uno M Sakurai H Ochi S Okada R Minami K Matsumoto YO Tanaka H Tsunoda S Homma H Yoshikawa 2007 High incidence of silent venous thromboembolism before treatment in ovarian cancer Br J Cancer 97 1053 1057 17895896 10.1038/sj.bjc.6603989 1:STN:280:DC%2BD2snhsFGntQ%3D%3D (Pubitemid 47587007)
25. K Uno S Homma T Satoh K Nakanishi D Abe K Matsumoto A Oki H Tsunoda I Yamaguchi T Nagasawa H Yoshikawa K Aonuma 2007 Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer Br J Cancer 96 290 295 17211468 10.1038/sj.bjc.6603552 1:CAS:528:DC%2BD2sXotFeksQ%3D%3D (Pubitemid 46164734)
26. S Koizume MS Jin E Miyagi F Hirahara Y Nakamura JH Piao A Asai A Yoshida E Tsuchiya W Ruf Y Miyagi 2006 Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII Cancer Res 66 9453 9460 17018600 10.1158/0008-5472.CAN-06-1803 1:CAS:528:DC%2BD28XhtVamsrnP (Pubitemid 44623642)
27. J Fang WN Wei LH Xia SJ Song 2004 The effects of tissue factor/activated factor VII complex on the invasion and metastasis of human ovarian cancer Chung Hua Hsueh Yeh Hsueh Tsa Chi 25 523 527 1:CAS:528:DC%2BD2MXps1ygt74%3D
28. LY Han CN Landen Jr AA Kamat A Lopez DP Bender P Mueller R Schmandt DM Gershenson AK Sood 2006 Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma J Clin Oncol 24 755 761 16380413 10.1200/JCO.2005.02.9181 1:CAS:528:DC%2BD28XitVGisbo%3D (Pubitemid 46622042)
29. BM Mueller RA Reisfeld TS Edgington W Ruf 1992 Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis Proc Natl Acad Sci USA 89 11832 11836 1465406 10.1073/pnas.89.24.11832 1:CAS:528:DyaK3sXpvFamtg%3D%3D (Pubitemid 23004738)
30. JL Yu L May V Lhotak S Shahrzad S Shirasawa JI Weitz BL Coomber N Mackman JW Rak 2005 Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis Blood 105 1734 1741 15494427 10.1182/blood-2004-05-2042 1:CAS:528:DC%2BD2MXhsVCqu74%3D (Pubitemid 40223697)
31. E Cocco Z Hu CE Richter S Bellone F Casagrande M Bellone P Todeschini G Krikun DA Silasi M Azodi PE Schwartz TJ Rutherford N Buza S Pecorelli CJ Lockwood AD Santin 2010 hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma Br J Cancer 103 812 819 20700124 10.1038/sj.bjc.6605760 1:CAS:528: DC%2BC3cXhtFaitL%2FF
32. WG Brodbeck C Mold JP Atkinson ME Medof 2000 Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack J Immunol 165 3999 4006 11034410 1:CAS:528:DC%2BD3cXntVyisbc%3D (Pubitemid 32057311)
33. XX Shi B Zhang JL Zang GY Wang MH Gao 2009 CD59 silencing via retrovirus-mediated RNA interference enhanced complement-mediated cell damage in ovary cancer Cell Mol Immunol 6 61 66 19254481 10.1038/cmi.2009.8 1:CAS:528:DC%2BD1MXktFGks74%3D
34. JR Ortaldo C Woodhouse AC Morgan RB Herberman DA Cheresh R Reisfeld 1987 Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies J Immunol 138 3566 3572 2437198 1:CAS:528:DyaL2sXktlOru7g%3D (Pubitemid 17071947)
35. RA Clynes TL Towers LG Presta JV Ravetch 2000 Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Nat Med 6 443 446 10742152 10.1038/74704 1:CAS:528:DC%2BD3cXisVOru7Y%3D (Pubitemid 30208162)
36. TA Fehniger EM Bluman MM Porter E Mrózek MA Cooper JB Van Deusen SR Frankel W Stock MA Caligiuri 2000 Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy J Clin Invest 106 117 124 10880055 10.1172/JCI6218 1:CAS:528:DC%2BD3cXks1yrsL4%3D (Pubitemid 30437247)
37. PC Caron LT Lai DA Scheinberg 1995 Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia Clin Cancer Res 1 63 70 9815888 1:CAS:528:DyaK2MXlvVarsrw%3D
38. G Krikun Z Hu K Osteen KL Bruner-Tran F Schatz HS Taylor P Toti F Arcuri W Konigsberg A Garen CJ Booth CJ Lockwood 2010 The immunoconjugate "icon" targets aberrantly expressed endothelial tissue factor causing regression of endometriosis Am J Pathol 176 1050 1056 20042667 10.2353/ajpath.2010.090757 1:CAS:528:DC%2BC3cXitFCmtrc%3D
39. TH Tezel E Bodek K Sonmez S Kaliappan HJ Kaplan Z Hu A Garen 2007 Targeting tissue factor for immunotherapy of choroidal neovascularization by intravitreal delivery of factor VII-Fc chimeric antibody Ocular Immunol Inflamm 15 3 10 10.1080/09273940601147760 1:CAS:528:DC%2BD2sXjslensL4%3D (Pubitemid 46328435)